UB Paderborn / Katalog / Suche / in CDI

1 – 15 von 15

Sortiert nach

Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters

Clinical and translational science, 2024-04, Vol.17 (4), p.e13799-n/a

2024

Volltextzugriff (PDF)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Pharmaceutics, 2022-07, Vol.14 (8), p.1530

2022

Volltextzugriff (PDF)

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes

The journal of clinical endocrinology and metabolism, 2020-06, Vol.105 (6), p.e2192-e2206

2020

Volltextzugriff (PDF)

First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug

Journal of antimicrobial chemotherapy, 2024-06, Vol.79 (6), p.1353-1361

2024

Volltextzugriff (PDF)

Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus

Diabetes research and clinical practice, 2019-06, Vol.152, p.125-134

2019

Volltextzugriff (PDF)

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

Nature medicine, 2024-03, Vol.30 (3), p.896

2024

Volltextzugriff (PDF)

Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo‐controlled first‐in‐human study in healthy volunteers

British journal of clinical pharmacology, 2022-02, Vol.88 (2), p.865-870

2022

Volltextzugriff (PDF)

Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients

British journal of clinical pharmacology, 2019-04, Vol.85 (4), p.704-714

2019

Volltextzugriff (PDF)

A Randomized, Double‐Blind, Single‐Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants

Clinical pharmacology in drug development, 2019-04, Vol.8 (3), p.361-370

2019

Volltextzugriff (PDF)

Bayesian Hierarchical Methods to Interpret the 13C-Octanoic Acid Breath Test for Gastric Emptying

Digestion, 2010-11, Vol.83 (1-2), p.96-107

2010

Volltextzugriff (PDF)

Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers

Advances in therapy, 2015-07, Vol.32 (7), p.650-661

2015

Volltextzugriff (PDF)

Application of bayesian statistics to physiological modelling

Vlasakakis, Georgios

2012

Volltextzugriff (PDF)

Bayesian hierarchical methods to interpret the (13)C-octanoic acid breath test for gastric emptying

Digestion, 2011, Vol.83 (1-2), p.96-107

2011

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(14)
Dissertationen
(1)

Sprache

Englisch
(15)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(8)
Pharmacokinetics
(7)
Male
(6)
Pharmacology & Pharmacy
(6)
Female
(5)
Adult
(4)
Medicine, Research & Experimental
(4)
Research & Experimental Medicine
(4)
Rifampin
(4)
Adolescent
(3)
Albiglutide
(3)
Drug Dosages
(3)
Glp-1 Receptor Agonist
(3)
Young Adult
(3)
Amoxicillin
(2)
Antitubercular Agents - Adverse Effects
(2)
Buruli Ulcer
(2)
Clavulanate
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes

First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug

Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo‐controlled first‐in‐human study in healthy volunteers

Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients

Comparison of 8 weeks standard treatment : study protocol for a randomized controlled multi-centre trial in Benin

A Randomized, Double‐Blind, Single‐Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants

Bayesian Hierarchical Methods to Interpret the 13C-Octanoic Acid Breath Test for Gastric Emptying

Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers

Application of bayesian statistics to physiological modelling

Bayesian hierarchical methods to interpret the (13)C-octanoic acid breath test for gastric emptying

Suchergebnisse filtern